Suppr超能文献

在2型糖尿病控制不佳患者中比较利格列汀与维格列汀的肾功能:一项在COVID-19大流行背景下的观察性研究。

Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic.

作者信息

Chaudhuri Sailayee, Biswas Supreeti, Mukhopadhyay Sandip, Dasgupta Somnath

机构信息

Department of Pharmacology, MJN Medical College and Hospital, Coochbehar, West Bengal, India.

Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal, India.

出版信息

Indian J Pharmacol. 2025 Jul 1;57(4):254-261. doi: 10.4103/ijp.ijp_492_24. Epub 2025 Jul 21.

Abstract

BACKGROUND

Dipeptidyl peptidase 4 (DPP-4) inhibitors are primarily excreted renally. Linagliptin is an exception with excretion primarily through enterohepatic system and is expected to have a better renal profile, though real-world data are scarce. Comparative studies on the renal safety and glycaemic control with linagliptin versus popular DPP-4 inhibitors such as vildagliptin are crucial, especially in the background of COVID-19 pandemic that hugely impacted glycemic control in India's large type 2 diabetes mellitus (T2DM) population.

MATERIALS AND METHODS

Adult T2DM patients not controlled with metformin alone, added linagliptin (5 mg once daily) or vildagliptin (50 mg twice daily) in the tertiary care outpatient department setting were included in the study. Parameters such as glycosylated hemoglobin, fasting blood glucose, postprandial blood glucose, blood urea nitrogen, serum creatinine, estimated glomerular filtration rate (eGFR), change in renal function, glycemic control, and clinical parameters were compared at baseline, 2 months, and 6 months of treatment. All adverse events were analyzed using the WHO-UMC scale.

RESULTS

Both groups achieved similar glycemic control, however, accompanied with impairment of renal parameters after 6 months. Compared to linagliptin, almost 300% rise in creatinine and 140% fall in eGFR were noted in the vildagliptin recipients. However, the difference in serum creatinine or eGFR could not attain statistical significance in the study.

CONCLUSION

Both linagliptin and vildagliptin can help to achieve glycemic control despite possible influence of the COVID-19 pandemic and are generally well tolerated. However, renal functions are better preserved with linagliptin. Further studies involving a larger sample size and longer follow-up are recommended before generalization of the findings of the present study.

摘要

背景

二肽基肽酶4(DPP-4)抑制剂主要经肾脏排泄。利那格列汀是个例外,其排泄主要通过肠肝系统,预计具有更好的肾脏安全性,尽管实际数据较少。比较利那格列汀与常用DPP-4抑制剂(如维格列汀)在肾脏安全性和血糖控制方面的研究至关重要,尤其是在新冠疫情对印度大量2型糖尿病(T2DM)患者血糖控制产生巨大影响的背景下。

材料与方法

本研究纳入了在三级医疗门诊环境中,单独使用二甲双胍血糖控制不佳,加用利那格列汀(每日一次,每次5mg)或维格列汀(每日两次,每次50mg)的成年T2DM患者。在治疗的基线、2个月和6个月时,比较糖化血红蛋白、空腹血糖、餐后血糖、血尿素氮、血清肌酐、估算肾小球滤过率(eGFR)、肾功能变化、血糖控制情况以及临床参数等指标。使用世界卫生组织药物不良反应监测中心(WHO-UMC)量表分析所有不良事件。

结果

两组患者血糖控制情况相似,但6个月后均出现肾脏参数受损。与利那格列汀组相比,维格列汀组患者肌酐升高近300%,eGFR下降140%。然而,血清肌酐或eGFR的差异在本研究中未达到统计学意义。

结论

尽管受到新冠疫情的可能影响,利那格列汀和维格列汀均有助于实现血糖控制,且总体耐受性良好。然而,利那格列汀对肾功能的保护更好。在本研究结果推广之前,建议进行样本量更大、随访时间更长的进一步研究。

相似文献

10
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.用于2型糖尿病的二肽基肽酶-4(DPP-4)抑制剂。
Cochrane Database Syst Rev. 2008 Apr 16;2008(2):CD006739. doi: 10.1002/14651858.CD006739.pub2.

本文引用的文献

5
Renoprotective Effects of DPP-4 Inhibitors.二肽基肽酶-4抑制剂的肾脏保护作用
Antioxidants (Basel). 2021 Feb 5;10(2):246. doi: 10.3390/antiox10020246.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验